Gastrointestinal Cancers Symposium (ASCO GI)

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.

T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.

Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.

GCC19CART generated responses in refractory metastatic colorectal cancer.

Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.

The phase 2 NeoCaCRT trial evaluating neoadjuvant SCRT plus cadonilimab/chemotherapy met its primary end point of pCR rate in locally advanced rectal cancer.

NAPOLI 3 post hoc findings show dose reductions of liposomal irinotecan or oxaliplatin did not worsen OS in pancreatic ductal adenocarcinoma.

The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.

Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.

ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.

Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.

Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.